DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx Biomedical Corporation, (OTCBB:QTXB.OB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has concluded the development of the Fieldtests ID product line for identifying drugs-of-abuse residue. QuantRx has entered into an exclusive manufacturing agreement with Fieldtests LLC. These new products represent a break-through technology for the field-testing of narcotic residues in both the law enforcement and occupational health marketplace.
